Citigroup Cuts Health Catalyst (NASDAQ:HCAT) Price Target to $3.25

Health Catalyst (NASDAQ:HCAT) had its target price lowered by Citigroup from $3.50 to $3.25 in a research report report published on Tuesday,Benzinga reports. The firm currently has a neutral rating on the stock.

HCAT has been the topic of a number of other research reports. Piper Sandler downgraded Health Catalyst from an “overweight” rating to a “neutral” rating and dropped their price objective for the stock from $8.00 to $4.00 in a research note on Wednesday, August 27th. UBS Group reiterated an “outperform” rating on shares of Health Catalyst in a research report on Tuesday. Weiss Ratings restated a “sell (d-)” rating on shares of Health Catalyst in a research report on Wednesday, October 8th. Canaccord Genuity Group lowered their price objective on shares of Health Catalyst from $9.00 to $5.00 and set a “buy” rating on the stock in a research note on Friday, August 29th. Finally, Evercore ISI cut their target price on shares of Health Catalyst from $4.00 to $3.00 and set an “in-line” rating for the company in a research note on Wednesday, October 8th. Five research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $4.36.

Health Catalyst Trading Down 4.5%

Shares of NASDAQ:HCAT opened at $2.35 on Tuesday. The company has a 50 day moving average of $2.99 and a 200-day moving average of $3.49. The company has a current ratio of 1.88, a quick ratio of 1.83 and a debt-to-equity ratio of 0.46. The firm has a market cap of $166.22 million, a P/E ratio of -1.48 and a beta of 1.64. Health Catalyst has a twelve month low of $2.20 and a twelve month high of $9.24.

Health Catalyst (NASDAQ:HCAT) last posted its quarterly earnings data on Monday, November 10th. The company reported $0.06 EPS for the quarter, beating analysts’ consensus estimates of $0.05 by $0.01. The business had revenue of $76.32 million for the quarter, compared to analyst estimates of $75.05 million. Health Catalyst had a negative net margin of 34.05% and a negative return on equity of 6.67%. Health Catalyst has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, analysts anticipate that Health Catalyst will post -0.33 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Health Catalyst

A number of large investors have recently made changes to their positions in the company. First Light Asset Management LLC lifted its position in shares of Health Catalyst by 17.2% in the 2nd quarter. First Light Asset Management LLC now owns 12,230,181 shares of the company’s stock valued at $46,108,000 after acquiring an additional 1,793,374 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Health Catalyst by 2.9% in the third quarter. Vanguard Group Inc. now owns 4,295,691 shares of the company’s stock valued at $12,243,000 after purchasing an additional 119,117 shares in the last quarter. Primecap Management Co. CA boosted its position in shares of Health Catalyst by 3.8% in the first quarter. Primecap Management Co. CA now owns 2,005,116 shares of the company’s stock worth $9,083,000 after buying an additional 72,499 shares during the period. Whetstone Capital Advisors LLC purchased a new position in shares of Health Catalyst during the first quarter valued at $7,724,000. Finally, Geode Capital Management LLC grew its holdings in shares of Health Catalyst by 11.4% during the second quarter. Geode Capital Management LLC now owns 1,662,455 shares of the company’s stock valued at $6,269,000 after buying an additional 169,580 shares in the last quarter. Institutional investors and hedge funds own 85.00% of the company’s stock.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.